A schedule for combined intravenous and oral dosing with mexiletine.
A combined intravenous and oral dosage regime for mexiletine has been evaluated in volunteer subjects. Therapeutically effective plasma concentrations of the drug were achieved rapidly and maintained over a four-hour period. Side-effects were minimal and the scheme would be suitable for the anti-arrhythmic protection of patients being transported to hospital and for the treatment of patients receiving hospital or, even, domicilliary care.
D000284:Administration, Oral; D000328:Adult; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008801:Mexiletine / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy; D011437:Propylamines / Q000008:administration & dosage*
D011437:Propylamines; D008801:Mexiletine